Rosuvastatin (Crestor) and rhabdomyolysis
Published Jul 20, 2004 · E. Wooltorton
Canadian Medical Association Journal
16
Citations
0
Influential Citations
Abstract
Reason for posting: Rosuvastatin (Crestor) is a relatively new cholesterol-lowering drug that has become one of the top-selling new pharmaceuticals since it was first marketed in Canada in February 2003. However, Health Canada recently alerted health care professionals of reports of rhabdomyolysis
Study Snapshot
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.